morphine sulfate

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

morphine hydrochloride

Doloral (CA), Morphitec (CA)

morphine sulfate, morphine sulphate

Astramorph PF, Avinza, Duramorph, Filnarine (UK), Filnarine SR (UK), Infumorph, Kadian, Morcap SR (UK), Morphogesic (UK), Morphogesic SR (UK), MS Contin, MST Continus (UK), MXL (UK), Novo-Morphine (CA), Oramorph SR (UK), Oramorph SR (UK), PMS Morphine Sulfate SR (CA), Ratio-Morphine Sulfate SR, Rhotard (UK), Sevredol (UK), Statex (CA), Sulfate SR (CA), Zomorph (UK)

Pharmacologic class: Opioid agonist

Therapeutic class: Opioid analgesic

Controlled substance schedule II

Pregnancy risk category C

FDA Box Warning

• Avinza (morphine sulfate) capsules are modified-release form indicated for once-daily P.O. administration to relieve moderate to severe pain requiring continuous, around-the-clock opioids for extended time. Instruct patients to swallow capsules whole or sprinkle contents on applesauce. Warn them never to chew, crush, or dissolve capsules or consume alcoholic beverages or use prescription or nonprescription drugs containing alcohol during therapy, as this may lead to rapid release and absorption of potentially fatal dose.

• Intrathecal dosage of morphine sulfate injection is usually one-tenth of epidural dosage.


Interacts with opioid receptor sites, primarily in limbic system, thalamus, and spinal cord. This interaction alters neurotransmitter release, altering perception of and tolerance for pain.

morphine hydrochloride

Rectal suppositories: 20 mg, 30 mg

Syrup: 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 50 mg/ml

Tablets: 10 mg, 20 mg, 40 mg, 60 mg

morphine sulfate

Capsules: 15 mg, 30 mg

Capsules (extended-release): 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 90 mg, 100 mg, 120 mg, 200 mg

Capsules (sustained-release): 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 100 mg

Oral solution: 2 mg/ml, 4 mg/ml, 20 mg/ml (concentrate), 10 mg/5 ml, 20 mg/5 ml, 100 mg/5 ml

Rectal suppositories: 5 mg, 10 mg, 20 mg, 30 mg

Solution for epidural injection (extended-release, liposomal): 10 mg/ml, 15 mg/1.5 ml, 20 mg/2-ml vials

Solution for epidural or intrathecal use (preservative free, for continuous microinfusion device): 10 mg/ml and 25 mg/ml in 20-ml vials

Solution for epidural or I.V. injection (preservative-free): 0.5 mg/ml, 1 mg/ml

Solution for I.M., I.V., or subcutaneous injection: 1 mg/ml, 2 mg/ml, 4 mg/ml, 5 mg/ml, 8 mg/ml, 10 mg/ml, 15 mg/ml, 25 mg/ml, 50 mg/ml

Solution for I.V. injection (for patient-controlled analgesia [PCA] device): 1 mg/ml, 2 mg/ml, 3 mg/ml, 5 mg/ml

Tablets: 15 mg, 30 mg

Tablets (controlled-release, sustained-release): 15 mg, 30 mg, 60 mg, 100 mg, 200 mg

Tablets (soluble): 10 mg, 15 mg, 30 mg

Indications and dosages

Severe to moderate pain

Oral use-

Adults: 5 to 30 mg P.O. (immediate-release) q 4 hours p.r.n. Or 20 mg P.O. (controlled-release, Kadian) once or twice daily p.r.n. Or 200 mg P.O. (MS Contin) in opioid-tolerant patients who require daily morphine-equivalent dosages above 400 mg.

I.M. or subcutaneous use-

Adults: 5 to 20 mg/70 kg I.M. or subcutaneously q 4 hours p.r.n.

I.V. use-

Adults: 2 to 10 mg/70 kg I.V. p.r.n. given slowly over 4 to 5 minutes. As a continuous I.V. infusion, 0.1 to 1 mg/ml in dextrose 5% in water delivered by controlled-infusion device.

Rectal use-

Adults: 10 to 30 mg P.R. q 4 hours p.r.n.

Epidural use-

Adults: Initially 5 mg (Astramorph PF, Duramorph) injected in lumbar region (may relieve pain up to 24 hours). If response isn't adequate within 1 hour, carefully give incremental doses of 1 to 2 mg p.r.n., up to 10 mg/24 hours. For continuous epidural infusion, 2 to 4 mg/24 hours. For epidural injection (DepoDur) before orthopedic leg surgery, recommended dosage is 15 mg; before lower abdominal or pelvic surgery, 10 to 15 mg. For cesarean section after umbilical cord clamping, recommended dosage is 10 mg.

Intrathecal use-

Adults: Usual intrathecal dosage is one-tenth of epidural dosage; 0.2 to 1 mg as a single injection in lumbar area may relieve pain up to 24 hours.

Dosage adjustment

• Adults weighing less than 50 kg (110 lb)

• Elderly patients

• Children


• Hypersensitivity to drug, tartrazine, bisulfites, or alcohol

• Acute bronchial asthma

• Upper airway obstruction

• Respiratory depression

• GI obstruction, paralytic ileus


Use cautiously in:

• head trauma; increased intracranial pressure; severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; prostatic hypertrophy

• elderly or debilitated patients

• pregnant or breastfeeding patients.


• For best response, give at pain onset.

• Give oral form with food or milk to minimize GI upset.

• If desired, crush immediate-release form and mix with food or fluids.

• Don't crush or break extended-release form; remind patient to swallow it whole.

• If desired, open sustained-release capsules (Kadian) and sprinkle entire contents onto small amount of food (such as applesauce). Have patient consume mixture immediately without chewing, crushing, or dissolving pellets.

• When giving by direct I.V., dilute in at least 5 ml of sterile water for injection or normal saline solution. Give 2.5 to 10 mg over 4 to 5 minutes.

• For continuous I.V. infusion, use infusion pump or PCA pump. Titrate dosage to provide adequate pain relief.

• Don't use parenteral form if it's cloudy or contains visible particulates.

Adverse reactions

CNS: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, nightmares

CV: hypotension, bradycardia

EENT: blurred vision, diplopia, miosis

GI: nausea, vomiting, constipation, dry mouth

GU: urinary retention

Respiratory: apnea, respiratory depression, respiratory arrest

Skin: flushing, itching, sweating

Other: physical or psychological drug dependence, drug tolerance


Drug-drug. Antihistamines, barbiturates, clomipramine, sedative-hypnotics, tricyclic antidepressants: additive CNS depression

Buprenorphine, butorphanol, dezocine, nalbuphine, pentazocine: decreased analgesia

Cimetidine: decreased morphine metabolism and increased effects

MAO inhibitors: severe, unpredictable reactions

Mixed opioid agonist-antagonists: precipitation of withdrawal symptoms in physically dependent patients

Warfarin: increased anticoagulant effect

Drug-diagnostic tests. Amylase, lipase: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

• Monitor vital signs. Contact prescriber if respiratory rate is 10 breaths/minute or less.

• Assess pain character, location, and intensity.

• Monitor fluid intake and output. Stay alert for urinary retention.

• Monitor bowel elimination pattern. If constipation occurs, intervene as appropriate.

• Assess neurologic status. Implement safety measures as needed to prevent injury.

• Evaluate patient for signs and symptoms of physical or psychological dependence. Be watchful for drug hoarding.

Patient teaching

• Tell patient he may crush immediate-release form and mix with food or fluids.

• Advise patient not to crush or break extended-release form. Instruct him to swallow it whole.

• Tell patient he may open sustained-release capsule (Kadian), sprinkle entire contents of capsule onto a small amount of food (such as applesauce), and consume immediately. Stress importance of not chewing, crushing, or dissolving pellets.

• Advise patient to take drug at the first sign of pain, because continuous dosing is more effective than p.r.n. dosing.

Tell patient and caregiver that drug may cause respiratory depression. Instruct them to immediately report respiratory rate of 10 breaths/minute or less.

• Inform patient that drug may cause constipation or urinary retention. Encourage high-fiber diet and high fluid intake.

• Stress importance of taking drug only as prescribed. Point out that drug may cause psychological or physical dependence.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.

• Teach patient and caregiver about appropriate safety measures to prevent injury.

• Caution patient to avoid alcohol and other CNS depressants during and for 24 hours after therapy.

• Advise patient to avoid herbs, which may worsen adverse CNS effects.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

mor·phine sul·fate (MS),

morphine used for formulation of tablets as well as solutions for parenteral, epidural, or intrathecal injection to relieve pain.

morphine sulfate

an opioid analgesic.
indications It is prescribed for relief of moderate to severe pain, including that from myocardial infarction and dyspnea caused by left heart failure, and as a preanesthetic.
contraindications Drug dependence or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are increased intracranial pressure, cardiovascular disturbances, respiratory depression, and drug dependence. Nausea, vomiting, constipation, and xerostomia are common.

mor·phine sul·fate

(mōr'fēn sŭl'fāt)
Agent used for formulation of tablets as well as solutions for parenteral, epidural, or intrathecal injection to relieve pain.

mor·phine sul·fate

(MS) (mōr'fēn sŭl'fāt)
Morphine used for parenteral, epidural, or intrathecal injection to relieve pain.
References in periodicals archive ?
A prospective double blind placebo controlled clinical trial was per- formed in 2010 by Ziegler et al6 evaluating the analgesic effects of morphine in patients with TMJD concluded that 10mg morphine sulfate intra-articular injection give the best and long lasting analgesic effect.
No adducted nucleotides could be detected on chromatograms prepared from cells treated either saline or mitomycin C followed by incubated with either saline of morphine sulfate for an additional 2 h.
In response to the outcry, the FDA sent follow-up letters on April 9 to six companies that offer the concentrated morphine sulfate elixir, saying they could continue to market the drug formulation.
Pharmaceutical products company Lannett Company (NYSE:LCI) reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate Oral Solution CII with added color and flavour in 20 mg/ml for acute and chronic pain.
Oral morphine sulfate appears to be a promising treatment for obsessive-compulsive disorder that is resistant to conventional therapies, Dr.
The five currently marketed products include morphine sulfate extended release capsules, the generic version of Kadian; fentanyl transdermal system CII, the generic equivalent of Duragesic; nifedipine extended release tablets, the generic version of Adalat CC; diltiazem hydrochloride extended release capsules, the generic equivalent of Cardizem CD; and metoclopramide hydrochloride tablets, the generic version of Reglan.
M2 PHARMA-August 9, 2012-Perrigo Company unveils FDA approved Morphine Sulfate 100ml/5% Oral Solution for moderate to severe acute and chronic pain(C)2012 M2 COMMUNICATIONS
has received approval of its ANDA for morphine sulfate extended-release tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.